An Open-Label Randomised Multi-Drug Biomarker-Directed Multi-Centre Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY)
Brief description of study
If you have been diagnosed with urothelial cancer, which has progressed after prior treatment, you may qualify to participate in a study. The main goal of this Phase Ib clinical trial is to evaluate if different combinations of novel anti-cancer agents are safe to use and what effects, good and/or bad, multiple agents of different novel anti-cancer agents as monotherapy and/or in combination have on you and your disease. In addition, we would like to study blood samples to understand the amount of drug present in your blood over time, which is known as pharmacokinetic (PK) testing.
Clinical Study Identifier: s15-00877
ClinicalTrials.gov Identifier: NCTs15-00877
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
